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Abstract  
 
Introduction 
Cyclophosphamide induction regimens are effective for ANCA-associated vasculitis, 
with remission rates of 80-90%. However, cyclophosphamide is associated with 
malignancies and infertility. Mycophenolate mofetil has been associated with high 
remission rates in small studies of ANCA-associated vasculitis.  
 
Methods 
We conducted a randomised controlled trial to investigate whether mycophenolate 
mofetil was non-inferior to cyclophosphamide for remission induction in ANCA-
associated vasculitis. 140 newly diagnosed patients were randomly assigned to 
mycophenolate mofetil or intravenous cyclophosphamide. All patients received the 
same oral glucocorticoid regimen and were switched to azathioprine following 
remission. The primary endpoint was remission by 6 months requiring compliance 
with the tapering glucocorticoid regimen.  
 
Results 
At baseline, ANCA subtype, disease activity and organ involvement were similar 
between groups. Non-inferiority was demonstrated for the primary remission 
endpoint, which occurred in 47 patients (67%) in the mycophenolate mofetil group 
and 43 patients (61%) in the cyclophosphamide group (RD 5.7%, 90%CI -7.5%–
19%). Following remission, more relapses occurred in the mycophenolate mofetil 
group (23 patients, 33%) compared to the cyclophosphamide group (13 patients, 19%) 
(IRR 1.97, 95%CI 0.96–4.23, p=0.049). Relapses in the mycophenolate mofetil group 
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were more frequent in patients with PR3-ANCA (48%) than MPO-ANCA (15%). 
Serious infections were similar between groups (26% mycophenolate mofetil group, 
17% cyclophosphamide group) (OR1.67 (95%CI 0.68 to 4.19, p=0.3).  
 
Conclusion 
Mycophenolate mofetil was non-inferior to cyclophosphamide for remission induction 
in ANCA-associated vasculitis, but was associated with more frequent relapse.  
(Clinical trials.gov number NCT00414128) 
 
 
Background 
 
ANCA-associated vasculitis{Jennette, 2013 #4232}, which includes Granulomatosis 
with polyangiitis (GPA) and microscopic polyangiitis (MPA), are rare potentially life-
threatening multisystem autoimmune diseases. They are frequently grouped together 
for the purpose of treatment trials given their similar initial responses to standard 
therapy{Mukhtyar, 2009 #4233;Hellmich, 2007 #3076}. Treatment for ANCA-
associated vasculitis comprises remission induction and maintenance 
regimens{Mukhtyar, 2009 #4233} (Mukhtyar 2009). Cyclophosphamide with high 
dose glucocorticoids has been standard remission induction therapy for severe 
ANCA-associated vasculitis for over 30 years with remission rates of 80%-
90%{Jayne, 2009 #3435;de Groot, 2009 #3239} and a current one year mortality of 
10-25%{Flossmann, 2011 #3648}. However; cyclophosphamide is toxic causing 
infertility and malignancy. Methotrexate has similar efficacy to cyclophosphamide for 
remission induction in non-severe ANCA-associated vasculitis, but is associated with 
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a high relapse rate and its toxicity precludes use in renal impairment{de Groot, 2005 
#2758} {Faurschou, 2012 #4234}. Rituximab, is associated with similar remission 
induction rates to those achieved with cyclophosphamide; and similar relapse rates 
over 18-24 months follow-up{Stone, 2010 #3538;Jones, 2010 #3549;Specks, 2013 
#4235;Jones, 2015 #4240}. However, the biological effect of rituximab is long and 
variable, and rituximab has been associated with hypogammaglobulinaemia in 
ANCA-associated vasculitis{Roberts, 2015 #4236}. Mycophenolate mofetil (MMF) 
is an alternative oral immunosuppressant with lymphocyte selective suppressive 
effects which is associated with similar remission rates to cyclophosphamide in lupus 
nephritis {Appel, 2009 #4237}. Mycophenolate has a short duration of action, can be 
used in renal disease and unlike cyclophosphamide is not associated with urothelial 
malignancy or infertility. Small studies have suggested that MMF has efficacy for 
remission induction in ANCA-associated vasculitis, particularly in MPO-ANCA 
disease{Han, 2011 #4239;Hu, 2008 #3011}  Understanding the role of MMF as a 
remission induction agent in ANCA-associated vasculitis is therefore important. We 
conducted a randomised trial of adult and paediatric patients to investigate whether 
MMF was non-inferior to cyclophosphamide for remission induction in new patients 
with ANCA-associated vasculitis. 
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Methods 
Study design and patients 
This trial was an open-label, two group, parallel design, randomised, non-inferiority 
trial involving 132 adult patients from 21 sites in six countries in Europe, Australia 
and New Zealand, and eight paediatric patients from four sites in the UK. All 
patients/parents provided written informed consent; and written assent where 
appropriate. Inclusion in this study required a new diagnosis of active ANCA-
associated vasculitis (GPA or MPA){Jennette, 2013 #4232}  with either a positive 
ANCA or histologically proven disease (see protocol for full inclusion details). 
Patients were excluded if they were aged < 6 years, had imminently life threatening 
vasculitis, rapidly declining renal function or an eGFR less than 15mls/min/m2. The trial 
protocol is available at http://www.vasculitis.org.  
Patients were randomised in a 1:1 ratio to MMF or cyclophosphamide. Randomisation 
was stratified according to: age, the planned use of additional therapy at 
randomisation, estimated glomerular filtration rate (eGFR) less than 30mls/min/m2 or 
greater than or equal to 30ml/min/m2. 
The trial was sponsored by Cambridge University Hospitals NHS Foundation Trust. 
Vifor Pharma (previously Aspreva Pharmaceuticals) provided a research grant to 
cover the trial and MMF costs. The trial protocol was designed by the ‘MYCYC’ trial 
steering committee, and received ethical and regulatory approval in each participating 
country. The trial was conducted according to the EU clinical trials directive 
(Directive 2001 EU/20/EC) (EUDRACT 2006-001663-33). Trial data is stored by the 
trial management committee at Addenbrooke’s Hospital, UK.  
 
Treatments 
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Before enrolment patients were permitted a maximum of two weeks prior treatment 
with cyclophosphamide or MMF and a maximum of 3g of intravenous 
methylprednisolone and/or plasma exchange. After randomisation, both groups 
received the same oral tapering glucocorticoid regimen (prednisolone 1mg/kg/day 
initially, reducing to 5mg/day at the end of 6 months, see appendix). Adult patients in 
the MMF group received MMF 2g/day, with dose increases to 3g/day permitted for 
uncontrolled disease at four weeks. Patients aged less than 17 years received a body 
surface area based MMF dosing regimen (see appendix). Patients in the 
cyclophosphamide group received a validated regimen of intravenous 
cyclophosphamide{de Groot, 2009 #3239}{Jones, 2010 #3549}  (see appendix). All 
patients were switched from their assigned study treatment to oral azathioprine 
2mg/kg/day after remission had been achieved, between 3-6 months. Azathioprine 
with prednisolone 5mg/day was continued until study end at 18 months.  
 
Assessments  
Assessments were performed at 0, 1, 1.5, 3, 4.5, 6, 9, 12, and 18 months and at the 
time of a relapse. Remission, for the primary endpoint, was defined as the absence of 
disease activity with a BVAS 2003 of zero on two consecutive occasions at least one 
month apart, and with compliance with glucocorticoid dosing according to the 
protocol within the same disease free period. A secondary remission endpoint was 
defined as remission by six months irrespective of glucocorticoid adherence. 
Progressive disease was defined as on-going disease activity of sufficient severity to 
necessitate therapy escalation with a change in immunosuppression or intravenous 
methylprednisolone before remission. Relapses could only occur after an initial 
remission (absence of disease activity, irrespective of glucocorticoid compliance, at 
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any time during trial follow-up). Patients who did not achieve an initial remission 
were excluded from relapse analyses. Relapses were defined as the recurrence or new 
appearance of any disease activity, as reflected by a BVAS 2003 > 0. Major relapse 
required the presence of one or more major BVAS items (see appendix). Renal 
function was assessed using eGFR, calculated using the 4 variable Modified Diet in 
Renal Disease (MDRD) equation in adults{Levey, 1999 #2899} or Haycock-
Schwartz formula in patients aged less than 16 years{Haycock, 1978 #4241}. End 
Stage Renal Disease (ESRD) was defined as dialysis dependence for six weeks or 
more without subsequent recovery of renal function. Serious adverse events were 
collected as defined by the European Medicines Agency and Food and Drug 
Administration. ANCA negativity was determined by the reference range of the local 
laboratory for both indirect immunofluorescence and enzyme linked immunosorbant 
assays. 
 
Outcomes  
The primary outcome was remission by six months. Secondary efficacy endpoints 
were time to remission, remission by six months irrespective of glucocorticoid 
adherence, progressive disease, relapse, cumulative glucocorticoid dosing, change in 
eGFR), Vasculitis Damage Index (VDI){Exley, 1997 #3837}, and ANCA positivity at 
six months. Planned subgroup analyses were the effect of eGFR, age and additional 
intravenous methylprednisolone and/or plasma exchange pre-randomisation on 
remission, and ANCA subtypes, on remission and relapse. Safety outcomes were 
serious adverse events, serious infections, ESRD, death, malignancy, cardiovascular, 
thromboembolic and serious disease related events. Outcomes were adjudicated by a 
committee blinded to study group assignment. 
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Statistical Analysis 
The sample size estimate was based on a non-inferiority design, that assumed the 
remission rate with MMF would be the same or higher than that seen with 
cyclophosphamide (i.e. truly non-inferior to cyclophosphamide), similar to that 
observed in lupus nephritis{Appel, 2009 #4237}. We assumed a remission rate of 
85% with cyclophosphamide and specified a 12% absolute risk difference as the non-
inferiority margin, based on the assumption that lower proportions of patients in 
remission at six months would be associated with worse clinical outcomes. Using 
these assumptions we calculated that 124 patients were required to meet non-
inferiority for the primary remission endpoint{Makuch, 1978 #4242} and allowing for 
a 10% drop out rate we recruited 140 patients. 
 
All endpoint analyses were by intention to treat with an additional pre-specified per 
protocol analysis of the primary endpoint.  The primary and secondary remission 
endpoints (non-inferiority) were assessed by calculating the risk difference (RD) of 
remission with corresponding two-sided 90% confidence intervals. For the primary 
analyses, no attempts were made to impute missing data.  Data were censored at 
withdrawal, loss to follow-up or death. Time to event analyses of remission (non-
inferiority) were performed using a Cox proportional hazards model with a hazard 
ratio (HR) of 0.85 as the non-inferiority margin.  Relapse rates (superiority) were 
compared by calculating the incidence rate ratio (relapses per patient per year) and 
corresponding 95% confidence interval. For safety and other efficacy endpoints 
comparison of proportions was performed using Fisher’s exact test. All analyses were 
conducted using Stata SE version 15 (College Station TX).
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Results 
Patients 
Between March 2007 and July 2011, 140 patients were enrolled in the study (66 
adults and four children in each treatment group). All patients received their allocated 
treatment and were retained for the primary analysis. By the end of the 6 month 
treatment period, four in each group had died, and three in the MMF group and two in 
the cyclophosphamide group had been lost to follow-up or had withdrawn consent 
(Figure 1, Table 1).  
 
Primary outcome 
The primary endpoint of remission with glucocorticoid compliance within 6 months 
occurred in 47 patients (67%) in the MMF and 43 (61%) in the cyclophosphamide 
groups (Absolute Risk Reduction (ARR) 5.7%, 90%CI -7.5%–19%). Given the 
specified margin of -12%, the lower bound of the 90% CI of -7.5% established non-
inferiority (Figure 2).  
 
In a pre-specified analysis restricted to per-protocol treated patients (see appendix), 43 
remissions (74%) occurred in 58 mycophenolate patients, compared to 33 remissions 
(62%) in 53 cyclophosphamide patients (ARR 11.9%, 90% CI -2.6%–26.3%, non 
inferior) (Figure 2). There was no evidence of interaction of PR3 ANCA positivity, 
age, renal function and the use of additional induction therapies with the primary 
endpoint (Figure 2).  
 
Secondary efficacy outcomes 
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Secondary efficacy outcomes are summarised in Figure 3, supplementary Table 1 and 
supplementary Figure 1. The time to primary remission in the MMF group (median 91 
days, IQR 44-95) was non-inferior to the cyclophosphamide group (median 87 days, 
IQR 42-91, HR 1.27 [90%CI 0.89–1.79, p=0.27]). 
 
Remission irrespective of steroid compliance within 6 months occurred in 61 patients 
(87%) in the MMF and 55 (79%) in the cyclophosphamide groups (ARR 8.6%, 
90%CI -1.8% to 19%). Remission at any time during trial follow up irrespective of 
steroid compliance occurred in 63 patients (90%) in the MMF and 64 (92%) of the 
cyclophosphamide groups (RD -1.4%, 90%CI -9.5%–6.6%). 
 
Progressive disease necessitating rescue therapy before remission occurred in five 
patients (7%) in the MMF and eight (11%) in the cyclophosphamide groups (p=0.56).  
 
At 6 months, 26 of 65 (40%) patients in the MMF group were ANCA negative, and 
21 of 65 (32%) patients in the cyclophosphamide group were ANCA negative (RR 
1.23, 95%CI 0.78 to 1.96, p=0.36). 
 
There were more relapses after remission in the mycophenolate group (23/63 patients; 
4 major and 19 minor relapses) compared with the cyclophosphamide group (13/64 
patients; 3 major and 10 minor relapses, IRR 1.97, 95% CI 0.96 to 4.23, p=0.049). 
Relapse free survival was shorter in the mycophenolate group (HR 2.14, 95% CI 1.07 
– 4.31, p=0.03).   
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In a subgroup analysis by ANCA subtype, 19 of 37 PR3-ANCA positive patients in 
the mycophenolate group relapsed, compared with 10 of 37 PR3-ANCA positive 
patients in the cyclophosphamide group (IRR 2.3, 95%CI 1.03 to 5.58, p=0.03). In 
MPO-ANCA positive patients, 4 relapses occurred in 25 patients in the 
mycophenolate mofetil group, and 3 relapses in 26 patients in the cyclophosphamide 
group (IRR 1.35, 95%CI 0.23 to 9.24, p=0.71).  
 
There was no difference in cumulative glucocorticoid exposure during the trial (MMF 
6194 ± 317 mg, CYC 5800 ± 234 mg, p=0.32) (Supplementary Figure 1a).  Two 
patients in both groups progressed to ESRD and eGFR at 18 months did not differ 
between groups (mycophenolate mofetil group 68±4 ml/min, cyclophosphamide 
group 64±4 ml/min, p=0.46) (Supplementary Figure 1b). There was no difference in 
disease and treatment related damage assessed by the vasculitis damage index at study 
end between the two groups (MMF=1, IQR 1 to 3; CYC=2, IQR 1 to 3; p=0.8). 
 
Safety outcomes 
 
Serious adverse events occurred in 35 in the MMF (50% patients, 73 events) and 28 in 
the cyclophosphamide groups (40% patients, 64 events) and are summarised in Table 
2. There was no difference in serious infections, death thromboembolism, malignancy 
or serious disease related events between the two groups. 
 
Discussion 
In this randomised trial of MMF versus cyclophosphamide for remission induction in 
severe ANCA-associated vasculitis, we demonstrated non-inferiority with MMF for 
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the primary remission endpoint requiring both absence of disease activity and 
compliance with glucocorticoid taper by both intention to treat and per protocol 
analyses. The relatively low remission rate for the primary outcome can be attributed 
to the stringent requirement for adherence to glucocorticoid taper as shown by 
others,{Stone, 2010 #3538} and the higher rate of the secondary endpoint of 
remission irrespective of glucocorticoid adherence is equally consistent with previous 
reports where glucocorticoid taper was not rigorously enforced. {Jayne, 2003 
#2377}{de Groot, 2009 #3239} We did not identify an interaction for the primary 
endpoint with age > 60 years, GFR < 30ml/min, the use of additional induction 
therapy or with PR3-ANCA positivity. Our results demonstrate that MMF represents 
a viable alternative to cyclophosphamide for remission induction in AAV. 
 
Our findings of comparable efficacy of MMF for remission induction compared to 
cyclophosphamide are consistent with previous MMF induction studies in AAV. 
However, it is notable that MMF was not superior to azathioprine for remission 
maintenance after cyclophosphamide induction, with numerically more relapses in the 
MMF group. {Hiemstra, 2010 #3637} Following remission induction all patients in 
our trial received azathioprine and glucocorticoid maintenance therapy. After 
remission, relapses occurred earlier and more frequently in the MMF group (33%) 
compared to the cyclophosphamide group (19%). This observation is similar to the 
increases in early relapses observed with methotrexate compared to 
cyclophosphamide{de Groot, 2005 #2758} as well as higher relapses with lower 
cumulative cyclophosphamide exposure{Harper, 2012 #3979}. Subgroup analyses 
revealed proportionally greater relapses in MMF patients with PR3-ANCA (48%) 
compared to MPO-ANCA (15%). Despite the lower background relapse risk for the 
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MPO-ANCA subgroup, the similarity in relapse rates between the two induction 
agents supports the hypothesis that MMF might be a valid alternative induction agent 
for MPO-ANCA. This hypothesis requires further investigation.   
 
The use of MMF alongside standard dose glucocorticoids offers advantages over 
cyclophosphamide in terms of fertility preservation for younger patients and 
potentially lower malignancy rates in elderly populations at greatest risk{Hellmich, 
2006 #4243}. Unlike rituximab (an approved alternative to cyclophosphamide for 
severe ANCA-associated vasculitis), MMF is an oral drug, has a short duration of 
action, and unlike methotrexate, can be used in moderate or severe renal disease and 
was not associated with slower time to remission compared to cyclophosphamide {de 
Groot, 2005 #2758}.  
 
Our trial has several notable strengths. It is the first randomised trial in AAV to assess 
the use of MMF for remission induction. Patients were recruited from 21 countries, 
and the trial cohort was representative of other trial populations in AAV. This is the 
first randomised trial in AAV to include children, and although the small number of 
paediatric participants (n=8) limit the inferences we might draw concerning relative 
efficacy of MMF in this population, inclusion of these patients increase the 
generalisability of these results and provide much needed data on treatment of 
childhood AAV. Further, the toxicity of cyclophosphamide makes MMF particularly 
attractive in the paediatric population. 
 
The strengths of our trial should be viewed against its limitations. The trial was not 
blinded, although the similar rates of glucocorticoid adherence and exposure, 
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progressive disease, rescue therapy requirement, ANCA negativity and the rates of 
ESRD is reassuring. Second, although our trial was relatively large for a rare disease, 
the inferences drawn from all subgroup analyses for the primary endpoint, and all 
secondary analyses, can only be viewed as exploratory. 
 
Death in ANCA-associated vasculitis is strongly associated with ESRD and older age. 
In this trial mortality was similar between groups (7% MMF, 6% cyclophosphamide 
groups) and similarly low compared to other trials excluding severe renal 
disease{Jayne, 2003 #2377}{de Groot, 2005 #2758}{de Groot, 2009 #3239}. Serious 
adverse event rates and serious infection rates did not differ between groups. 
Improved short term safety with MMF was not demonstrated {Appel, 2009 
#4237}{Ginzler, 2005 #4247}. 
 
In summary we observed non-inferiority with MMF compared to cyclophosphamide 
for remission induction of AAV alongside a standard high dose glucocorticoid 
tapering regimen. Relapses were higher in the MMF group, most notably in the PR3-
ANCA patient subgroup, highlighting the importance of initial induction regimen on 
subsequent relapse risk.  
 
Our results suggest that with standard high dose glucocorticoids, MMF is a potential 
alternative to cyclophosphamide for remission induction in non-life threatening, 
ANCA-associated vasculitis. With increasing remission induction treatment options 
for AAV, stratified treatment approaches are indicated in order to optimise long term 
outcomes. 
. 
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Table and Figure legends 
Figure 1. Randomization and inclusion in the analysis at 18 months 
Figure 2.  Absolute risk ratio for the primary remission endpoint, per-protocol and 
subgroup analyses 
Figure 3. Remission and relapse 
a. Time to primary remission   
b. Time to first relapse  
c. Time to first relapse stratified by ANCA-PR3 and ANCA-MPO subtype 
Table 1. Baseline characteristics of the patients at trial entry 
Table 2. Serious adverse events 
Supplementary Figure 1. Other secondary outcomes 
a. Glucocorticoid dosing  
c. Glomerular filtration rate  
b. Vasculitis Damage Index 
Supplementary Table 1. Summary of efficacy outcomes 
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Tables and Figures  
Figure 1. Randomization and inclusion in the analysis at 18 months 
 
  
 
 
 
 
 
 
140 patients randomised 
70 assigned to the 
mycophenolate mofetil group 
70 assigned to the control 
group 
64 remained in the trial at 6 
months 
64 remained in the trial at 6 
months 
70 were included in the 
analyses at 18 months 
70 were included in the 
analyses at 18 months 
62 remained in the trial at 18 
months 
64 remained in the trial at 18 
months 
Before 6 months 
4 died 
2 withdrawals/lost to 
follow up 
Before 6 months 
4 died 
2 withdrawals/lost to 
follow up 
At 18 months 
5 died 
3 withdrawals/lost to 
follow up 
At 18 months 
4 died 
2 withdrawals/lost to 
follow up 
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Figure 2. Absolute risk ratio for the primary remission endpoint, per-protocol and 
sub-group analyses 
 
 
 
The diamonds represent the absolute risk ratio, horizontal black lines represent 90% 
confidence intervals. The left side of blue shaded area represents the lower limit of non-
inferiority margin (-12%).  
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Figure 3. Remission and relapse 
a. Time to primary remission 
 
 
 
Primary remission was remission with no disease activity and glucocorticoid protocol 
compliance. Analysis was censored at the first of the following events; remission (first 
BVAS of zero), six month study visit, withdrawal or death.  
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b. Time to first relapse  
 
 
Relapse could only occur after an initial remission. Remissions for this analysis are not 
restricted to the first 6 months of follow-up, but represent remissions occurring at any 
time point after randomisation irrespective of glucocorticoid compliance. Time to first 
relapse was significantly quicker in the mycophenolate mofetil group.  
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c. Time to relapse stratified by ANCA-PR3 and ANCA-MPO subtypes 
 
 
 
 
More relapses occurred in the MMF group than the cyclophosphamide group. A post-
hoc subgroup analysis found the higher relapse rate in MMF patients was accounted 
for by more relapses in PR3 ANCA patients, but not MPO ANCA patients.  
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Table 1. Baseline characteristics of the patients at trial entry. 
 
Variable Mycophenolate 
mofetil group 
(N=70) 
 
Cyclophosphamide 
group 
 
(N=70) 
Age (yrs) – median (IQR) 60 (48-70) 61 (53-68) 
Paediatric <18 years (%) 4   (6) 4   (6) 
Male sex – no. (%) 41 (59) 33 (47) 
Diagnosis – no. (%) 
GPA 
MPA 
 
47 (67) 
23 (33) 
 
44 (63) 
26 (37) 
ANCA – no. (%) 
PR3 or cANCA 
MPO or pANCA 
Negative 
 
41 (59) 
28 (40) 
1 (1) 
 
42 (60) 
26 (37) 
2 (3) 
ANCA ELISA – no. (%) 
PR3-ANCA 
MPO-ANCA 
Negative 
 
40 (57) 
27 (39) 
3 (4) 
 
42 (60) 
26 (37) 
2 (3) 
eGFR at entry, ml/min/m2 - median (IQR) 
All patients 
Patients with renal disease 
 
51 (29-92) 
47 (27-70) 
 
51 (31-79) 
46 (29-74) 
Organs involvement* – no. (%) 
Renal 
Lung 
ENT 
 
57 (81) 
30 (43) 
41 (59) 
 
57 (81) 
35 (50) 
38 (54) 
BVAS# – median (IQR) 19 (13-25) 18 (14-23) 
CRP (mg/L) - median (IQR) 22 (7.5-52) 19 (5-83) 
ESR (mm/hr) – median (IQR) 54 (31-98) 59 (33-90) 
Cyclophosphamide pre-randomisation   
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Patients - no. (%) 
Total dose (grams) – median (IQR) 
17 (24) 
1 (0.55-1.1) 
22 (31) 
1 (0.6-1.07) 
IV methylprednisolone pre-randomisation  
Patients - no. (%) 
Total dose (grams) – median (IQR) 
 
41 (59) 
1.5 (1.5-3) 
 
35 (50) 
1.5 (1.5-2) 
Plasma exchange pre-randomisation 
Patients - no. (%) 
Total exchanges – median (IQR) 
 
8 (11) 
5 (5-7) 
 
4 (6) 
7 (6-7) 
 
* Renal involvement is defined as one or more renal BVAS items present at entry 
excluding hypertension alone. Lung and ENT require one or more lung or ENT BVAS 
items present at entry respectively. #Baseline BVAS data was missing in 1 subject in 
the mycophenolate mofetil group.  
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Table 2. Serious Adverse Events 
 
 Mycophenolate mofetil 
group  
(n=70) 
Cyclophosphamide group  
(n=70) 
Significance 
 All events 
 
Patients with 
≥1 event 
All events Patients with ≥1 
event 
 
 
 No. No. (%) No. No. (%) 
 
 
All serious adverse events  
 
73 35 (50) 64 28 (40) P=0.30 
Serious events by category 
 
     
Infections 
 
29 18 (26) 16 12 (17) P=0.30 
End stage renal disease 
 
2 2 (3) 2 2 (3) P=1.0 
Death 
 
5 5 (7) 4 4 (6) P=1.0 
Malignancy 
 
1 1 (1) 1 1 (1) P=1.0 
Cardiovascular 
 
6 3 (4) 6 5 (7) P=0.72 
Disease related events 
 
16 10 (14) 9 7 (10) P=0.61 
Thromboembolism 
 
2 2 (3) 2 2 (3) P=1.0 
 
Five mycophenolate patients died (7%) (causes of death were cardiac n=1, infections 
n=2 and other n=2) and four cyclophosphamide patients died (6%) (causes of death 
were cardiac n=1, infections n=2 and other n=1) (OR 1.27 (0.26 to 6.68, p=1.0). 
Median age at death was 75 years (range 73 to 82 years) in the mycophenolate group 
and 83 years (range 63 to 85 years) in the cyclophosphamide group. Malignancies 
were liver metastases of unknown primary in a 74 year old in the mycophenolate 
group and a malignant melanoma in a 63 year old in the cyclophosphamide group 
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Supplementary Figure 1. 
 
A. Cumulative steroid exposure 
 
 
Boxes represent median (IQR), whiskers represent the nearest adjacents (nearest value 
to 1.5 times the IQR from the median). Dots represent outliers. 
 
B. Change in glomerular filtration rate 
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Data points represent individual values for change from baseline eGFR (ml/min/m2) 
over actual time. Lines represent the fitted linear regression values of change in eGFR 
over time. 
 
 
C. Vasculitis damage index 
 
 
The figure shows individual VDI values over time for the two groups. Scatter plots 
show individual values with jitter in both axes for clarity. Lines represent the fitted 
quadratic regression lines for VDI over time.
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Supplementary table 1. Efficacy Outcomes 
 MMF 
group  
(n=70) 
CYC 
group  
(n=70) 
Point estimates Non-
inferiority 
margin 
Significance 
Primary endpoint      
Primary remission – no. (%) 47 (67) 43 (61) ARR 5.7%, 90%CI -7.5% to 
19% 
-12% Non-inferior 
Per protocol* analysis – no (%) 
 
43/58 () 33 (53) ARR 11.9%, 90%CI -2.6% 
to 26.3% 
-12% Non-inferior 
Secondary endpoints      
Remission      
§Time to primary remission by (6 
months) 
  HR 1.27, 90%CI 0.89 – 
1.79, p = 0.27 
0.85 Non-inferior 
Remission by 6 months 
irrespective of steroid compliance 
– no. (%) 
63 (90) 56 (80) RD 10%, 90%CI -2%–22% -12% Non-inferior 
Remission at any time 
irrespective of steroid compliance 
– no. (%) 
63 (90) 64 (91) RD -1.4%, 90%CI -9.5%–6.6% -12% Non-inferior 
 
Progressive disease – no. (%) 5 (7) 8 (11) – Superiority 0.56 
 
Relapse – no. (%) 
All patients 
Time to first relapse 
PR3 positive at entry 
MPO positive at entry 
 
 
23 (33) 
 
19/40 (48) 
4/27 (15) 
 
13 (19) 
 
10/42 (24) 
3/26 (12) 
 
IRR 1.97, 95%CI 0.96–4.23 
HR 2.14, 95%CI 1.07 – 4.31 
IRR 2.31, 95%CI 1.03–5.58 
IRR 1.35, 95%CI 0.23–9.24 
 
Superiority 
 
 
 
 
 
0.049 
0.03 
0.029 
0.71 
 
Major relapses 4 (6) 3 (4) IRR 1.48, 95%CI 0.25–10.13  0.63 
Time to major relapse   HR 2.4, 95%CI 0.44–13.13  0.31 
 
Minor relapses 19(27) 10(14) IRR 2.11, 95%CI 0.93–5.09  0.053 
Time to minor relapse   HR 2.09, 95%CI 0.97–4.5  0.059 
      
RD – Risk Difference; HR – Hazard Ratio; IRR – Incidence Risk Ratio.  
  28
 
*The per protocol analysis was performed as an additional analysis for the primary endpoint and included patients who adhered to their assigned 
study treatment regimen (see appendix) for the first 6 weeks of the trial and did not receive additional intravenous steroids or immunomodulatory 
treatments. 29 patients were excluded from the per protocol analysis (MMF 12, CYC 17).  
§ For the time to remission analysis, remissions were defined as for the primary endpoint. 
